Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.200
+0.090 (8.11%)
At close: May 12, 2025, 4:00 PM
1.200
0.00 (0.00%)
After-hours: May 12, 2025, 7:59 PM EDT
Company Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada.
The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil.
Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Milestone Pharmaceuticals Inc.
| Country | Canada |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Joseph Oliveto |
Contact Details
Address: 1111 Dr. Frederik-Philips Boulevard, Suite 420 Montreal, QC H4M 2X6 Canada | |
| Phone | 514-336-0444 |
| Website | milestonepharma.com |
Stock Details
| Ticker Symbol | MIST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001408443 |
| CUSIP Number | 59935V107 |
| ISIN Number | CA59935V1076 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph G. Oliveto M.B.A. | Chief Executive Officer, President and Director |
| Amit Hasija | Chief Financial Officer and Executive Vice President of Corporate Development |
| Dr. David B. Bharucha FACC, M.D., Ph.D. | Chief Medical Officer |
| Dr. Philippe Douville M.B.A., Ph.D. | Founder, Strategic Advisor and Member of Scientific Advisory Board |
| Jeffrey Nelson | Chief Operating Officer |
| Kim Fox | Vice President of Communications |
| Roshan Girglani | Vice President of Marketing |
| Jeff Moore | Vice President of Sales |
| Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. | Chief Medical Advisor and Member of the Scientific Advisory Board |
| Dr. Guy Rousseau | SVice President of Regulatory Affairs and Quality Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 30, 2025 | SCHEDULE 13G/A | Filing |
| Apr 22, 2025 | SCHEDULE 13G/A | Filing |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 424B5 | Filing |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 13, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |